Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conversion Therapy With Ipilimumab N01, Sintilimab, Bevacizumab Biosimilar, and HAIC for uHCC
NCT07560488Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2026
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab in hepatocellular carcinoma (HCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Conversion resection rate at 1 year. Started Mar 2026; status: recruiting.
02
Drugs
ipilimumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07560488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07560488.